Ralliant (NYSE:RAL – Get Free Report) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.580-0.640 for the period, compared to the consensus earnings per share estimate of 0.520. The company issued revenue guidance of $540.0 million-$556.0 million, compared to the consensus revenue estimate of $529.0 million. Ralliant also updated its FY 2026 guidance to 2.530-2.690 EPS.
Ralliant Stock Performance
Shares of RAL opened at $49.36 on Tuesday. The company has a market cap of $5.52 billion and a PE ratio of 25.18. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average price of $44.32 and a 200-day moving average price of $47.07. Ralliant has a 12-month low of $37.27 and a 12-month high of $57.02.
Ralliant (NYSE:RAL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter. The business had revenue of $534.60 million for the quarter. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts forecast that Ralliant will post 2.37 earnings per share for the current fiscal year.
Ralliant Dividend Announcement
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on RAL shares. Vertical Research upgraded Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Friday, February 6th. Barclays decreased their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Citigroup decreased their price objective on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Royal Bank Of Canada decreased their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 6th. Finally, Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.50.
Check Out Our Latest Analysis on RAL
Insider Buying and Selling at Ralliant
In related news, SVP Karen M. Bick sold 5,485 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares of the company’s stock, valued at approximately $2,104,020. This trade represents a 10.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Hedge Funds Weigh In On Ralliant
Large investors have recently bought and sold shares of the stock. Palisade Asset Management LLC purchased a new position in Ralliant in the 3rd quarter worth approximately $26,000. BOKF NA purchased a new position in Ralliant in the 3rd quarter worth approximately $29,000. Wilmington Savings Fund Society FSB purchased a new position in Ralliant in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC purchased a new position in Ralliant in the 2nd quarter worth approximately $39,000. Finally, NewEdge Advisors LLC purchased a new position in Ralliant in the 2nd quarter worth approximately $43,000.
About Ralliant
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Read More
- Five stocks we like better than Ralliant
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
